STUDY DESIGN AND METHODS:
Seventeen trauma centers using group A plasma in trauma patients of unknown ABO group participated in this study. Eligible patients were group A, B, and AB trauma patients who received at least 1 unit of group A plasma. Data collected included patient sex, age, mechanism of injury, Trauma Injury Severity Score (TRISS) probability of survival, and number of blood products transfused. The main outcome of this study was in-hospital mortality differences between group B and AB patients compared to group A patients. Data on early mortality (24 hr) and hospital LOS were also collected.
RESULTS: There were 354 B and AB patients and 809
A patients. The two study groups were comparable in terms of age, sex, TRISS probability of survival, and total number of blood products transfused. The use of group A plasma during the initial resuscitation of traumatically injured patients of unknown ABO group was not associated with increased in-hospital mortality, early mortality, or hospital LOS for group B and AB patients compared to group A patients.
CONCLUSION:
These results support the practice of issuing thawed group A plasma for the initial resuscitation of trauma patients of unknown ABO group. P lasma transfusion is an important part of the initial resuscitation of trauma patients and maintaining an immediately available plasma inventory is crucial for timely delivery of plasma in this setting. 1 For patients of unknown ABO group, group AB is the universal plasma donor group as it does not contain anti-A or anti-B. Unfortunately, only 4% of the US donor population is group AB making this a scarce and precious resource. 2 Use of group AB thawed plasma for trauma resuscitation may be challenging for blood banks due to a limited supply of this blood component. At lowvolume trauma centers, a trauma case may not occur within the thawed plasma 5-day shelf life. Any unused group AB thawed plasma would then be administered to a non-group AB recipient or wasted. The use of group A plasma for trauma patients of unknown blood group has previously been proposed as an alternative to group AB. [3] [4] [5] [6] [7] [8] A recently published survey revealed that the use of group A plasma in the initial resuscitation of trauma patients of unknown ABO group is becoming a widespread practice in the United States. maintain an inventory of immediately available group A plasma, and 63% use group A plasma in the initial phase of the resuscitation of trauma patients of unknown ABO group. At half of the centers, using group A plasma is a relatively new practice having started within the past year (as of the time the survey was conducted in January 2015). Further, most of the centers (62%) do not limit the amount of group A plasma that can be administered to trauma patients and only 21% of the respondents indicated that anti-B titer is a criterion for choosing group A plasma units for emergency issue. Thus, using group A plasma in trauma patients of unknown ABO group is a common event, despite the paucity of data demonstrating its safety. There are several reasons why the safety of this practice has up to now been assumed. First, traumatic blood loss is replaced with group O red blood cells (RBCs) in the initial part of the resuscitation effort when the recipient's ABO group is unknown. These transfused group O RBCs reduce the volume of the autologous RBCs that could be susceptible to hemolysis from group A plasma. Second, 80% of group B and AB recipients (i.e., those who are potentially susceptible to hemolysis from group A plasma) will be secretors of soluble B substance that would neutralize the anti-B present in the group A thawed plasma. 10 Third, the experience from the transfusion of minor mismatched platelets (PLTs) has demonstrated that hemolysis from group A PLTs is uncommon. 11 Fourth, 80% to 85% of unknown trauma victims will be group O or group A, and therefore group A plasma will be compatible with their blood group.
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This study retrospectively examined outcome data from centers where group A plasma is used during the initial resuscitation of traumatically injured patients of unknown ABO group. Based on the Trauma Injury Severity Score (TRISS) probability of survival, 12,13 the primary outcome of this study was in-hospital mortality differences between trauma patients who received group A plasma and were later confirmed to be group B and group AB compared to those who were later confirmed to be group A. Secondary outcomes included early (24 hr) mortality and hospital length of stay (LOS) differences between these two groups of recipients.
MATERIALS AND METHODS
This multicenter study retrospectively collected data on consecutive injured group A, B, and AB patients admitted to adult Level 1 or 2 trauma centers where group A plasma is issued in the massive transfusion protocol (MTP) and is routinely administered to trauma patients of unknown ABO group. To be included in the study, all patients had to have received at least 1 unit of group A plasma during their initial resuscitation period. The start of the initial resuscitation period was defined as the time when the MTP was activated and the end of the initial resuscitation period as the time when the last blood product had been issued before there was a more than 6-hour continuous period where no blood products were issued. Group A trauma patients who received only ABOidentical plasma during the initial resuscitation were defined as the "identical" study group. Receipt of minor mismatched PLTs did not exclude these patients from being included in the identical group. The outcomes from these group A patients were compared to those who were group B and AB, who were defined as the "incompatible" group. Similarly, receipt of ABO-identical PLTs did not exclude these patients from being included in the incompatible group. Group O trauma patients were excluded from this study as group A plasma is neither ABO identical nor incompatible for this ABO group.
Existing hospital records were retrospectively reviewed to obtain the following demographic and clinical data for all study participants: date of admission, date/time of MTP activation, and all subsequent blood products issued until a more than 6-hour period elapsed when no products were issued, date of birth or age at time of admission in years, sex, ABO/D group, mechanism of injury (blunt vs. penetrating trauma), admission systolic blood pressure, respiratory rate and Glasgow Coma Score (or calculated Revised Trauma Score using these data), admission Injury Severity Score, predicted TRISS probability of survival (calculated from Revised Trauma Score, Injury Severity Score, age, and mechanism of injury), date/time of discharge or death, and LOS in days. Patients with incomplete and/or missing study data were excluded.
The types and total number of all blood products transfused (RBCs, plasma, PLT doses, and cryoprecipitate pools of 4-6 whole blood units) during the initial resuscitation were recorded for each study patient. The total number of group A plasma units as a subset of the total number of plasma units transfused during the initial resuscitation period was also determined for each patient.
Each participating site investigated whether any reports of suspected transfusion reactions were received by the transfusion service through their institution's routine reporting mechanism for possible transfusion reactions. The physician interpretation of the suspected transfusion reaction was obtained for all reported reactions in study patients.
The study period varied by participating center and was defined as the time from the implementation of group A plasma use for trauma patients of unknown ABO group, through the end of June 2016. Participating centers utilized institution-specific MTPs and criteria for activating the MTP for trauma resuscitation. Participating centers also followed their respective institutional policies regarding the use of group A plasma (e.g., volume limitations and/or whether or not an anti-B titer threshold was employed in choosing group A plasma units). This study was approved by the institutional review or research ethics board at each participating institution.
Statistical analysis
The primary outcome of this study was in-hospital mortality. The study sample size calculations were based on a 30% probability of in-hospital mortality and projected that 371 patients would be required in each study group (i.e., identical vs. incompatible) to have 80% power of detecting a 10% increase in in-hospital mortality with a two-tailed significance level of 0.05. Secondary outcomes included early mortality (defined as death within the first 24 hr of admission) and hospital LOS.
Chi-square analysis was used to assess the significance of any differences in the categorical variables (sex, mechanism of injury, proportional 24-hr mortality, and inhospital mortality). The t test was used to assess the significance of any differences in the continuous variables (age, TRISS probability of survival, numbers of blood products transfused during the initial resuscitation, and hospital LOS; GraphPad Software). Logistic regression analyses were also performed (R software, https://www.rproject.org/).
The Z statistic was calculated for each group. This statistical tool compares the actual number of deaths in each study group to the predicted number of deaths based on the TRISS probability of survival. 12, 13 When studying mortality, a negative value for a Z statistic implies that that number of deaths predicted by the TRISS probability of survival exceeds the number of deaths observed in the study group. A Z statistic with an absolute value that is greater than 1.96 indicates a significance level of 0.05.
The M statistic was calculated to measure the degree of similarity in TRISS probability of survival between the two groups. M values range from 0 to 1 and the closer to 1, the higher the degree of matching for TRISS probability of survival between study groups. M values of less than 0.88 indicate an unacceptably low degree of matching between study groups.
RESULTS
A total of 17 trauma centers participated in this study (16 in the United States and one in the United Kingdom). Study data were obtained for 1163 trauma patients with 809 (70%) group A patients in the identical group and 354 (30%) group B or AB patients in the incompatible group.
Participating centers varied widely in terms of the numbers of study patients contributed. This likely reflects differences in trauma volumes and different start dates for the use of group A plasma for trauma patients of unknown ABO group. Although the majority of participating centers implemented use of group A plasma after January 2014, some participating centers have been using group A plasma for trauma patients of unknown ABO group since as early as 2008. The majority of participating centers (76%) do not perform titration on the group A plasma to determine the anti-B titer, but among those that do, the critical titer is most frequently less than 50 (i.e., no agglutination at a 1:50 saline dilution). The majority of participating centers (65%) also do not impose limits on the number of group A plasma units that patients can receive, but among those that do, the limits range from 4 to 10 units (Table 1) .
There were no significant differences in patient age, sex, or the TRISS probability of survival between the two study groups. The incompatible group had a higher incidence of penetrating injury compared to the identical group (p < 0.0001). There were no significant differences in the total number of blood products transfused during the initial resuscitation period other than the expected finding that group A patients received more group A plasma units (p < 0.0001; Table 2 ). Using a chi-square analysis, there was no difference in the primary outcome of in-hospital mortality between the two groups with rates of 29% observed in each study group (p 5 0.83). There were also no significant differences in the secondary outcomes of early mortality (24 hr) or hospital LOS (Table 3) . A logistic regression analysis was performed for overall in-hospital mortality as a linear combination of the following predictor variables: age, sex, mechanism of injury, TRISS, and category of compatibility (identical vs. incompatible). In this analysis, the only significant predictor variables were age and TRISS score (p 5 0.05 and p 0.0001, respectively). Additionally, we performed a logistic regression analysis for 24-hour survival as a linear combination of the same predictor variables. The only significant predictor variable was the TRISS score (p 0.0001).
Both study populations had fewer deaths than predicted by the TRISS probability of survival based on the Z statistic. The identical group had a Z score of 25.61 while the incompatible group had a Z score of 23.52. The negative values indicate that the number of deaths observed in each group was less than the expected number of deaths predicted by the TRISS probability of survival (p < 0.001). 13 The M statistic of 0.95 indicates a high degree of matching in terms of TRISS probability of survival between the two groups. 13 There were seven acute transfusion reactions reported in the identical group (0.9%; four allergic, one transfusion-associated circulatory overload, one acute hemolytic due to anti-Fy a , and one febrile nonhemolytic). There were no acute transfusion reactions reported in the incompatible group.
DISCUSSION
This study is the largest to date that examines the use of group A plasma during the initial resuscitation of traumatically injured patients of unknown ABO group. We found no increase in early mortality, in-hospital mortality, or LOS of group B or AB patients compared to group A patients. Despite most (76%) of the participating centers not measuring anti-B titers in group A plasma units before release, there were no reported acute hemolytic transfusion reactions attributable to ABO incompatibility. Thus it appears safe to utilize group A plasma as the first option for trauma patients of unknown ABO group, a finding consistent with, and confirmatory of, those of recent smaller studies. 5, 6, 8 The safety of transfusing plasma that is ABO compatible but not identical (such as group A plasma to a group O recipient) has been questioned but could not be answered in this study as group O recipients were excluded from analysis. 14 Only five of our study subjects were younger than 15 years of age; therefore, we consider our conclusion to apply only to adult trauma patients (defined by American College of Surgeons as 15 years).
As with any retrospective study, the results of this study should be interpreted in the context of study limitations. Although the intent was to capture data on sequential traumatically injured patients of unknown ABO group receiving group A plasma during the initial resuscitation, patients were not randomized and study data were collected retrospectively so some patients may have been excluded due to missing study data (the number of such patients is unknown).
As with any multicenter study, there are also known and unknown differences between centers in transfusion and trauma resuscitation practices that could influence study outcomes. Centers differed in both group A plasma titration practices and in limits on the number of units of group A thawed plasma that could be issued to trauma patients of unknown ABO group (Table 1) . We also did not collect data to determine transfusion practices for trauma patients for whom an historic ABO group was on file in the transfusion service. Some participating centers may elect to give group A plasma to these patients while others may provide type-specific blood product support.
There were no differences in the number of blood products transfused during the initial resuscitation between study groups except for an increased number of group A plasma units transfused to patients in the identical group. This finding is expected as these patients would continue to receive group A plasma once switched to type-specific blood product support.
This study did not collect data on the ABO group of PLTs transfused. It is likely that patients in both study groups received exposure to incompatible plasma through PLT transfusions. Although patients in both groups received the same mean number of PLT doses (whole blood pools or apheresis unit), the most aggressively resuscitated patients received up to 23 PLT doses in the identical group and up to 16 doses in the incompatible group. The impact of any incompatible plasma received from PLT transfusions on study outcomes is unknown.
Both study groups had higher rates of in-hospital survival than would be predicted based on the TRISS probability of survival (71% actual vs. 64% predicted for the identical group and 71% actual vs. 66% predicted for the incompatible group). The resulting Z-scores are significant. These better than predicted outcomes likely reflect advances in trauma care that improve outcomes for all patients.
This study was not designed to detect hemolysis or complications of hemolysis associated with the receipt of group A plasma in the incompatible group. Thus, it is possible that receipt of group A plasma in the incompatible group could have caused some degree of morbidity that did not end in mortality; this study was not designed to detect such morbidity, but rather the main outcomes of this study were focused on mortality endpoints. Based on the routine practice of transfusion of group O apheresis PLTs to non-O patients, clinically significant hemolysis would be expected to be quite rare. 11 Furthermore, recent single-center data examining the use of group O whole blood in trauma patients of unknown ABO group has not revealed changes in any of the biochemical markers that would be suggestive of hemolysis or renal failure among non-group O recipients. 15 Very large prospective controlled trials would be necessary to determine whether clinically significant hemolysis or renal failure occurs in the setting of transfusion of group A plasma to group B and AB patients. Although data were collected on any acute transfusion reactions reported to the transfusion service during the initial resuscitation of study patients, transfusion reaction reporting rates were low. Transfusion reaction reporting practices also likely differ between participating institutions. While no acute transfusion reactions were reported in the incompatible group, prospective studies with active surveillance for transfusion reactions would be necessary to determine whether transfusion of group A plasma increases the rate of acute transfusion reactions in group B and AB patients.
There were several other limitations to this study. Data on the number of blood products transfused before and after the MTP period were not collected; thus perhaps patients actually received more group A plasma than what was reported. However, even with this possibility, there were no mortality or LOS outcome differences between the two groups. Furthermore, the mean LOS was not adjusted for those who died. This could have led to a shortening of the mean LOS; however, the percentage mortality was not significantly different between the two groups at both time points. Thus, any artificial reduction in the LOS caused by patients who died would be expected to affect both groups equally. Finally, this study was not designed or powered to detect a dose effect related to the amount of group A plasma transfused in the incompatible group.
This multicenter retrospective study is the largest study published to date examining the impact of using group A plasma during the initial resuscitation of traumatically injured patients of unknown ABO group on mortality and hospital LOS. These data demonstrate that the transfusion of incompatible group A plasma to group B and AB trauma patients does not appear to be associated with higher rates of in-hospital or early mortality or longer hospital LOS compared to group A trauma patients who receive identical group A plasma. Results of this study support the practice of issuing group A plasma for the initial resuscitation of traumatically injured patients of unknown ABO group.
